Tolerogenic nanoparticles suppress central nervous system inflammation

Area of Science:

• Immunology
• Nanotechnology
• Neuroscience

Background:

• Therapeutic immune tolerance is crucial for autoimmune diseases like multiple sclerosis (MS).
• The aryl hydrocarbon receptor (AhR) is a key regulator of immune responses and a potential target for immunotherapy.

Purpose of the Study:

• To develop novel nanoliposomes (NLPs) that activate the AhR for antigen-specific tolerance induction.
• To evaluate the efficacy of these NLPs in preclinical models of multiple sclerosis.

Main Methods:

• Engineered NLPs loaded with an AhR agonist (ITE) and a myelin oligodendrocyte glycoprotein (MOG) T cell epitope.
• Administration of NLPs in preventive and therapeutic settings in experimental autoimmune encephalomyelitis (EAE) models.
• Analysis of immune cell populations, including regulatory T cells (Treg and Tr1) and effector T cells (Teff), and disease progression.

Main Results:

• NLPs induced tolerogenic dendritic cells and suppressed EAE development.
• Suppression correlated with increased MOG-specific Treg and Tr1 cells and decreased CNS-infiltrating Teff cells.
• NLPs demonstrated bystander suppression and ameliorated chronic progressive EAE in different mouse models.

Conclusions:

• AhR-activating NLPs represent a promising platform for inducing antigen-specific tolerance.
• This approach holds potential for treating autoimmune diseases, including multiple sclerosis.
• The developed NLPs show therapeutic efficacy in preclinical models, suggesting a novel immunotherapy strategy.